Intraocular anti-VEGF injection therapy is the most recently developed and most effective treatment method for wet type age related macular degeneration. While the rate of decrease in vision was slowed down with the old treatments, some visual improvement could be achieved with intavitreal injection anti-VEGF treatments. Anti-VEGF drugs with contemporary ingredients bevacizumab, ranibizumab and aflibercept are currently available in the market. Intraocular injection treatment begin with 3 monthly loading doses after the diagnosis of wet type age related macular degeneration. Patients are followed up for 1-2 months apart, and the injection is nat made or re-injected if necessary, depending on the results of the examination and optical coherence tomography findings. Patients mostly express their concerns about getting an injection in his/her eye, but these worries are unnecessary since it is a painless and very shorttime procedure most of the time. After the injection, the patient can go home and continue his normal life. Due to the risk of infection, patients are warned not to rub their eyes after the injection, and antibiotic drops are given to prevent infection for a few days.

Another group of diseases in which intravitreal injection therapy is applied is macular (yellow spot) edema due to diabetes or retinal vein occlusions. Intraocular injection treatments are also successfully applied in these diseases.